



INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard, et al. (as amended herein)
App. No : 10/063,569
Filed : May 2, 2002
For : SECRETED AND
TRANSMEMBRANE POLYPEPTIDES
AND NUCLEIC ACIDS ENCODING
THE SAME
Examiner : Hunnicutt, Rachel Kapust
Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 7, 2005

(Date)

Marc T. Morley, Reg. No. 52,051

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing twenty-nine (29) references to be considered by the Examiner. Also enclosed are fifteen (15) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

04/11/2005 GWORDDF1 00000027 10063569

03 FC:1806

180.00 OP

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 7, 2005

By:

Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 30,313
(619) 235-8550

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/063,569
	Filing Date	May 2, 2002
	First Named Inventor	Goddard, Audrey
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Hunnicut, Rachel Kapust
SHEET 1 OF 2	Attorney Docket No.	GNE.3230R1C49

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,536,637	07-16-1997	Jacobs	
	2	6,025,156	02-15-2000	Gwynn, et al.	
	3	6,124,433	09-26-2000	Falb, et al.	
	4	6,156,500	12-05-2000	Falb, Dean	
	5	6,162,604	12-19-2000	Jacob, Chaim O.	
	6	6,228,582	05-08-2001	Rodier, et al.	
	7	6,395,306	05-28-2002	Cui, et al.	
	8	6,414,117	07-02-2002	Levinson, D. A.	
	9	6,465,185	10-15-2002	Goldfine, et al.	
	10	6,498,235	12-24-2002	Sheppard, et al.	
	11	6,562,343	05-13-2003	Levinson, D. A.	
	12	6,645,499	11-11-2003	Lal, et al.	
	13	6,730,502	05-04-2004	Van Hijum, et al.	
	14	6,737,522	05-18-2004	Sundick, et al.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	16	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell</i> 4th Edition, pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	17	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	
	18	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. <i>Molecular and Cellular Biology</i> , 1720-1730.	
	19	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	20	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. <i>Cancer Research</i> , 62:6240-6245.	
	21	LEWIN, B. 1994. <i>Oncogenes: Gene Expression and Cancer</i> , Chap. 39, pp.1196-1201. <i>Genes V</i> . New York: Oxford University Press.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/063,569
	Filing Date	May 2, 2002
	First Named Inventor	Goddard, Audrey
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Hunnicut, Rachel Kapust
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	22	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	23	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	24	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	25	OKA, et al. NCBI Accession No. AB031481, December 8, 1999.	
	26	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
	27	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	28	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (<i>HER-2/neu</i>) oncogene. <i>Pathol. Annu</i> , 1(27):165-190.	
	29	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. <i>World Journal of Surgical Oncology</i> , 2:13.	

1536619
040605

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.